Switzerland Archives

News and Trends 29 Oct 2015

Naughty Novartis…US Department of Justice Fines them $390M – Again!

Being a multi-billion international Pharmaceutical giant does not protect you from the Law…and in my best American accent “Justice WILL be served” (and bang! goes the gavel). Novartis gets called out on their dodgy sales boosting techniques again down the US Federal court. Novartis has been caught out serving Pharmacists and Doctors under the table […]

October 29, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Oct 2015

Wow, Europe’s leading CRISPR Biotech signs monster €2.29 Billion Deal

CRIPSR’s hype is not going down yet. CRIPSR/Cas9 or Cpf1 is a revolutionising gene editing tool, which almost won the Nobel Prize of this year (it won nearly all the other biology prizes already). It also caught great interest from the industry and venture capitalists. The leading Biotechs includes: Editas, Boston-based and clozed a $120M found […]

October 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 26 Oct 2015

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

October 26, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 23 Oct 2015

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Novartis, the Swiss Biotech giant, has once again broadened its Immuno-oncology portfolio with the acquisition of US Admune Therapeutics (MA) and forming marketing, commercialization and development partnerships with California’s Xoma and Palobiopharma in Barcelona (Spain). Novartis is a Basel giant in the biotech industry, with their research development programs spanning a broad range of fields […]

October 23, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Oct 2015

Synbio Perfumery: Making Smells and Flavors with Microbes

Isobionics is a biotech from the Netherlands that specializes in synthetic bio-production of natural essential oils and flavorings for use in the food, perfume and detergent industry. On the other hand, Evolva, from Basel, are estimated to produce up to $500M worth of synthetic vanilla essence for the industry each year. Using bacteria and yeast […]

October 19, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

No, Novartis and Roche won’t merge (yet)!

Novartis already owns 33% of Roche, but even if both companies are headquartered in the same city of Basel (Switzerland), they still have no plans to merge. Joerg Reinhardt, The Chairman of Novartis – the second biggest Pharma company worldwide by market cap (€212Bn – J&J: €231Bn), was asked about it on the Swiss TV Bilanz […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Oct 2015

Why can’t Novartis Commit to the Israeli Biotech Scene?

Novartis, the Swiss Acquisition-Giant from Basel, has once again taken bought a small chunk of shares from the Israel biotech scene for only $15M (2.5%), instead of making a final solid purchase. The Jerusalem biotech Gamida Cell, which has a stem-cell therapies for hematological diseases (leukemia and various types of anemia), was underwhelmed a second […]

October 13, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 6 Oct 2015

Sony DADC re-purposing Blu-Ray Technology for Clinical Immunoassays

Sony Digital Audio Disc Corporation (Sony DADC) BioSciences is a DVD and Blu-ray disc manufacturer headquartered in Salzburg (Austria). A new collaboration with FIONASTICS (an immunoassay specialist) means they will use their Blu-Ray tech to develop a new nanostructure platform for fluorescent immunoassays. These will be developed for use in detection of clinical biomarkers for […]

October 6, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 1 Oct 2015

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Paris based Sofinnova continues to invest in the Alzheimer’s fight, with a €27.5M pot given to Swiss Asceneuron (originally a spin-off from Merck-Serono). Sofinnova therefore joins other investors such as JJDC in the new and optimistic biotech wave of therapies for neurodegenerative diseases like Alzheimer’s and progressive supranuclear palsy (PSP). The last decade has been fairly […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Sep 2015

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

CRISPR is already revolutionizing Biotechnology. However, like every biotech revolution, there then follows a patent war. But the discovery of a new gene editing protein (Cpf1), with the potential of replacing Cas9, could change this status-quo. As Business Insider puts its, CRISPR is “the biggest biotech discovery of the century“. And its true, it really changed […]

September 30, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 29 Sep 2015

A Cartridge system to revolutionize diagnosis time of infective pathogens?

Canada’s Axela partners up with Swiss Hutman Diagnostics to test the cartridge based detection kit with their pan-European infectious disease resources. The Alena System could revolutionize time and cost of diagnosing bacterial pathogens in meningitis, endocarditis and hospital-acquired infections etc. Hutman Diagnostics is originally from Basel (Switzerland) having been founded in 2011 as a developer […]

September 29, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

Will Roche lose its Worldwide Leading position in Cancer treatments?

Roche is the worldwide leader in cancer treatments, but it’s threatened by the increasing competition of biosimilars and the development of next-generation cancer drugs. Is there a risk for the “biggest Biotechnology company worldwide” to lose its leading position on the lucrative anti-cancer business? The Swiss giant makes massive amount of cash with its cancer treatments, […]

September 29, 2015 - 4 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

Naughty Novartis…US Department of Justice Fines them $390M – Again!

Wow, Europe’s leading CRISPR Biotech signs monster €2.29 Billion Deal

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Synbio Perfumery: Making Smells and Flavors with Microbes

No, Novartis and Roche won’t merge (yet)!

Why can’t Novartis Commit to the Israeli Biotech Scene?

Sony DADC re-purposing Blu-Ray Technology for Clinical Immunoassays

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

A Cartridge system to revolutionize diagnosis time of infective pathogens?

Will Roche lose its Worldwide Leading position in Cancer treatments?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!